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Comprehensive miRNA expression 
profiling in human T-cell acute 
lymphoblastic leukemia by small 
RNA-sequencing
Annelynn Wallaert  1,2, Wouter Van Loocke1, Lucie Hernandez3, Tom Taghon2,4, Frank 
Speleman1,2 & Pieter Van Vlierberghe  1,2
T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease that can be classified 
into different molecular genetic subtypes according to their mRNA gene expression profile. In this 
study, we applied RNA sequencing to investigate the full spectrum of miRNA expression in primary 
T-ALL patient samples, T-ALL leukemia cell lines and healthy donor thymocytes. Notably, this analysis 
revealed that genetic subtypes of human T-ALL also display unique miRNA expression signatures, 
which are largely conserved in human T-ALL cell lines with corresponding genetic background. 
Furthermore, small RNA-sequencing also unraveled the variety of isoforms that are expressed for 
each miRNA in T-ALL and showed that a significant number of miRNAs are actually represented by an 
alternative isomiR. Finally, comparison of CD34+ and CD4+CD8+ healthy donor thymocytes and T-ALL 
miRNA profiles allowed identifying several novel miRNAs with putative oncogenic or tumor suppressor 
functions in T-ALL. Altogether, this study provides a comprehensive overview of miRNA expression 
in normal and malignant T-cells and sets the stage for functional evaluation of novel miRNAs in T-ALL 
disease biology.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that is classified into 
different genetic subtypes based upon the aberrant expression of specific transcription factor oncogenes (TAL, 
TLX1, TLX3 or HOXA) or the arrest at a specific stage of T-cell differentiation (immature T-ALL)1–4. Notably, 
these molecular subgroups are characterized by unique mRNA and long non-coding RNA expression signatures, 
which partially reflect their putative cell of origin1, 2, 5.
MicroRNAs (miRNAs) are short non-coding RNAs that function as post-transcriptional repressors of specific 
target genes6, 7. Several studies have previously described a role for miRNAs in malignant T-cell transformation, 
including the identification of both an oncogenic (miR-19b, mir-20a, miR-26a, miR-92 and miR-223)8 as well as a 
tumor suppressor (miR-150, miR-155, miR-200 and miR-193b-3p)9, 10 miRNA network involved in T-ALL disease 
biology. However, studies that addressed the role of miRNAs in human T-ALL have largely been focused on pre-
viously recognized miRNA molecules as they consistently used RT-qPCR or microarrays as detection platforms.
More recently, small RNA-sequencing emerged as a more comprehensive technology that enables unbiased 
detection of the full spectrum of small RNA molecules. In addition, it also provides information on specific iso-
forms that differ from canonical miRNAs by the addition or deletion of one or more nucleotides at the 5′ or 3′ end 
of the miRNA11, 12. Notably, this heterogeneity in miRNA sequences, which is thought to result from RNA-editing, 
exonuclease activity or imprecise cleavage by DICER or DROSHA (ribonucleases involved in the miRNA process-
ing)13, could be functionally relevant as shown for a number of miRNAs14–17.
Here, we used small RNA-sequencing to study the full spectrum of miRNAs that are expressed in human 
T-ALL samples. We demonstrate, for the first time, that molecular genetic subtypes of human T-ALL are char-
acterized by unique miRNA expression signatures, delineate the pattern of miRNA isoforms that are expressed 
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in malignant T-cells and use small RNA sequencing profiles of normal T-cell subsets to identify novel putative 
oncogenic or tumor suppressive miRNAs in the context of human T-ALL.
Results
Small RNA-sequencing of T-ALL patient samples, healthy donor thymocytes and T-ALL cell 
lines. To study the full spectrum of miRNAs involved in normal and malignant T-cell development, we per-
formed small RNA-sequencing on 48 primary T-ALL patient samples of different T-ALL subgroups (13 immature, 
14 TLX1+ or TLX3+, 15 TAL-rearranged and 6 HOXA-overexpressing T-ALL samples), CD34+ and CD4+CD8+ 
normal thymocyte subsets from healthy donors and a panel of 7 T-ALL cell lines (Fig. 1a). While 1816 miRNAs 
were initially detected in the total panel of T-ALL patient samples, we further only considered the 574 miRNAs 
for which four reads were present in at least 60% of patients from one T-ALL subtype (Fig. 1b).
Given that we previously performed miRNA expression profiling using the same T-ALL patient cohort using 
an RT-qPCR approach10, we were able to directly compare the results from the RT-qPCR study with our small 
RNA-sequencing effort. Using a similar background selection as mentioned above, 283 miRNAs were previously 
detected by RT-qPCR10, which converted into 248 unique miRNAs that are currently annotated in the most recent 
version of miRBase18. From these, 198 miRNAs were also detected using our current small RNA-sequencing 
approach. Therefore, the RT-qPCR approach still detected 50 miRNAs that were not identified in the small 
RNA-sequencing dataset. In contrast, small RNA sequencing detected 259 miRNAs, that were not included in a 
previous RT-qPCR analysis from the same T-ALL patient population10.
In Fig. 1b and Supplementary Fig. S1, the mean expression values for the 574 miRNAs, detected by small 
RNA-sequencing in primary T-ALL patients, are plotted, with the black dots representing the 280 miRNAs that 
were previously identified by RT-qPCR and the red dots representing the miRNAs detected for the first time in 
human T-ALL. Most of the formerly known miRNAs reside amongst the most highly expressed in human T-ALL 
Figure 1. Small RNA-sequencing of T-ALL samples, healthy thymocytes and cell lines detects novel T-ALL 
miRNAs and isomiRs. (a) Overview of samples profiled by small RNA-sequencing. (b) Dot plot representing 
the mean normalized expression levels of all 574 miRNAs detected by small RNA-sequencing of the 48 T-ALL 
patient samples. Each dot represents one miRNA and the miRNAs are ranked from highest to lowest mean 
expression. Black dots are miRNAs that were already detected by a qRT-PCR platform from previous studies. 
Red dots are the novel miRNAs detected in T-ALL samples. (c) Bar plot visualizing the distribution of the 
miRNAs by means of the amount of isomiRs they are represented by. (d) Correlation plot between the mean 
expression level of the miRNAs and their amount of isomiR forms. (e) Table representing the isomiR form that 
was represented by the highest expression level for each of the detected miRNAs. The first column denotes the 
5′ overhangs or deletions, the second column the 3′ overhang or deletions of the isomiR in comparison to the 
canonical miRNA. The third column shows the amount of miRNAs of which the highest expressed miRNA had 
that isomiR form. (Graphics from www.somersault1824.com).
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(Fig. 1b). However, some of the newly identified miRNA transcripts in T-ALL also show a very high expression 
pattern (the top 10 of highest expressed novel miRNAs are annotated in Fig. 1b), suggesting that they might 
possess oncogenic potential in the context of T-ALL disease biology. Nevertheless, the average expression level of 
most novel T-ALL miRNAs that were exclusively detected by small RNA-sequencing is median to low.
Small RNA-sequencing also enables the detection of so-called isomiRs, i.e. miRNA isoforms that deviate from 
the canonical sequence by one or a few nucleotide(s)11, 12. In our small RNA-sequencing dataset, we identified 
2139 isomiRs covering 481 different miRNAs, losing some very low expressed miRNAs from the analysis above. 
Although 154 miRNAs were only represented by one isomiR, some others showed expression of more than 10 
different isomiR forms (Fig. 1c). We observed a positive correlation between the number of isomiRs detected for a 
specific miRNA and its expression level in human T-ALL (r = 0.89, Fig. 1d). For example, we detected 39 different 
isomiR forms for miR-181a-5p, the miRNA that shows the highest average expression in T-ALL. Remarkably, 
for 106 out of 481 miRNAs, the canonical miRNA was not expressed in our patient series. In addition, for only 
half of the miRNAs (246 out of 481), the canonical isoform showed the highest expression level, suggesting that 
a substantial amount of miRNAs are mainly represented by alternative isomiRs. The distribution of isomiRs that 
show the highest expression for each miRNA is shown in Fig. 1e.
Small RNA-sequencing reveals a subtype specific expression pattern of miRNAs in human 
T-ALL. Previous studies have convincingly shown that molecular genetic subtypes of human T-ALL dis-
play unique mRNA1, 2 and lncRNA5 expression signatures. Here, we used the 574 miRNAs detected by 
small RNA-sequencing to define subtype specific miRNA expression signatures in human T-ALL (adjusted 
p-value < 0.05; Fig. 2a; Supplementary Table S1). Principal Component Analysis confirmed that the most pro-
nounced differences in miRNA expression are observed between immature and TAL-R T-ALL patient samples 
(Fig. 2b). Of note, although TLX1 and TLX3 patients have previously been considered as one genetic entity, 
miRNA based clustering did reveal some differences between members of the TLX subtype (Fig. 2b). For exam-
ple, the miRNA expression signature of a specific subset of TLX3 positive T-ALLs is clearly more related to imma-
ture T-ALL, which was not observed for any of the TLX1 positive leukemias (Fig. 2b). The 10 miRNAs that show 
the highest expression level in each of the genetic subtypes are shown in Fig. 2c. The miRNAs, which were not 
previously detected by the RT-qPCR platform, are depicted in red (Fig. 2c).
As mentioned above, small RNA-sequencing was also performed on a panel of 7 human T-ALL cell lines. 
These in vitro model systems reflect most of the different genetic subtypes of human T-ALL and included TLX1/3 
positive (ALL-SIL, DND41 and HPB-ALL), TAL-R positive (PF-382, JURKAT and KE-37) and immature/HOXA 
overexpressing (LOUCY) tumor lines. Notably, based on the miRNAs represented in Fig. 2a, most T-ALL cell 
lines clustered separate from the T-ALL patient samples, with the exception of LOUCY, which clustered together 
with immature T-ALL patient samples, and ALL-SIL (Supplementary Fig. S2). Nevertheless, subtype specific 
miRNAs, which were identified in primary T-ALL patient samples, also showed high expression in the T-ALL cell 
lines from their corresponding genetic subtype (Fig. 2d and Supplementary Fig. S3). Therefore, the subtype spe-
cific tumor lines can be used as valuable in vitro tools to evaluate the role of specific miRNAs in the pathogenesis 
of this disease.
MiRNA profiling of normal thymocyte subsets reveals oncogenic subtype specific miR-
NAs. Small RNA-sequencing was also performed on CD34+ and CD4+CD8+ normal thymocyte samples 
from two healthy donor controls. First, DESeq2 analysis revealed 190 miRNAs that show significant differential 
expression between these CD34+ and CD4+CD8+ normal T-cell subsets (126 high in CD34+ and 64 high in 
CD4+CD8+; adjusted p-value < 0.05; Fig. 3a and Supplementary Table S2). The top ten most significant miRNAs 
are listed in Fig. 3b, with the miRNAs depicted in red those that were not covered in previous RT-qPCR analyses. 
Of note, small RNA-sequencing data were highly concordant between both donors for each subset (Fig. 3c and 
Supplementary Fig. S4).
Next, we integrated these miRNA expression data obtained from healthy donors with the subtype specific 
miRNAs that were identified in the primary T-ALL patient cohort. For example, 4 miRNAs (hsa-miR-222-3p, 
hsa-miR-146a-5p, hsa-mir-221-3p and hsa-miR-126-5p) from the top 10 immature T-ALL specific miRNAs 
(Fig. 2c) also showed significant higher expression in CD34+ vs. CD4+CD8+ T-cell subsets (Fig. 4a). Similarly, 
three miRNAs (hsa-miR-16-5p, hsa-miR-16-2-3p and hsa-miR-450b-5p) from the top 10 TAL-R specific miRNAs 
(Fig. 2c) are significantly upregulated in CD4+CD8+ T-cell subsets (Fig. 4b). Therefore, these miRNAs most 
probably reflect the specific T-cell maturation arrest associated with these molecular genetic subtypes of T-ALL 
and their respective cell of origin.
In order to identify miRNAs with putative oncogenic potential in specific T-ALL subgroups, we also per-
formed differential expression analysis between immature T-ALLs and CD34+ thymocytes, and between TAL-R 
T-ALLs and CD4+CD8+ thymocytes, as these thymocyte subsets represent the stage of differentiation arrest 
during T cell development leading to these specific T-ALLs (Supplementary Tables S3 and S4). From the top 
ten immature specific miRNAs, three miRNAs (hsa-miR-21-5p, hsa-miR-222-3p and hsa-miR-101-3p) were sig-
nificantly upregulated in the immature samples compared to the healthy control CD34+ samples. Remarkably, 
hsa-miR-222-3p was also significantly upregulated in the CD34+ subset, but its expression is further increased in 
immature T-ALLs (Fig. 4c). Similarly, three miRNAs (hsa-miR-182-5p, hsa-miR-29c-3p and hsa-miR-450b-5p), 
from the TAL-R subtype specific signature, show significant higher expression in the TAL-R T-ALLs as com-
pared to their CD4+CD8+ normal counterparts. Here, hsa-miR-450b-5p was already higher expressed in the 
CD4+CD8+ double positive subset, but showed a further increase in activity in TAL-R rearranged leukemias 
(Fig. 4d).
www.nature.com/scientificreports/
4SCIENTIFIC REPORTS | 7: 7901  | DOI:10.1038/s41598-017-08148-x
Small RNA-sequencing reveals novel putative oncogenic miRNAs in human T-ALL. Finally, we 
aimed to identify novel T-ALL miRNAs with potential oncogenic activity in human T-ALL irrespective of the 
genetic subtypes. Differential expression analysis between 48 T-ALL samples and four normal thymocyte samples 
(Supplementary Table S5) resulted in the identification of 87 significantly upregulated miRNAs and 69 down-
regulated miRNAs in human T-ALL (Fig. 5a). Several miRNAs with a known oncogenic role in T-ALL8, 19 were 
recovered from this analysis and are depicted in Fig. 5a. However, and most notably, this analysis also identified 
different miRNAs, which were not previously detected in the context of normal and malignant T cell develop-
ment, and which could potentially act as novel oncomiRs or tumor suppressor miRNAs involved in the biology 
of this disease (Fig. 5b,c).
Figure 2. Small RNA-sequencing of primary T-ALL samples reveals a subtype specific expression pattern of 
miRNAs. (a) Heatmap representing the top 50 most significantly up- or downregulated miRNAs per subgroup 
in comparison to the other subgroups (adjusted p-value < 0.05). (b) PCA-plot showing the distribution of the 
patient samples. The different colors denote patient samples from a different subgroup. (c) Table representing 
the selection of 10 miRNAs per subgroup. These were the highest expressed miRNAs that were significantly 
upregulated in that subgroup compared to the other subgroups. MiRNAs denoted in red were not detected by 
a previously used qRT-PCR platform. (d) Density plots representing the distribution of the miRNA expression 
in the LOUCY, HPB-ALL and JURKAT cell line. Vertical bars show the expression level of the top 10 miRNAs 
selected for the subgroup these cell lines represent. LOUCY represents the immature T-ALL subgroup, HPB-
ALL the TLX1/3 subgroup and JURKAT the TAL-R subgroup.
www.nature.com/scientificreports/
5SCIENTIFIC REPORTS | 7: 7901  | DOI:10.1038/s41598-017-08148-x
Figure 3. MiRNA profiling of healthy thymocyte subsets reveals different miRNA expression profiles between 
CD34+ and CD4+CD8+ subsets. (a) Diagonal plot showing the expression of the miRNAs in the different 
thymocyte subsets. Red dots represent miRNAs that are significantly higher expressed in the CD34+ subset, 
blue dots are the miRNAs significantly higher expressed in the CD4+CD8+ subset. (b) Top 10 most significantly 
upregulated miRNAs for the CD34+ subset and for the CD4+CD8+ subset. MiRNAs denoted in red were not 
detected by a previously used qRT-PCR platform. (c) Dot plots of two representative miRNAs for the subsets. 
**Significant difference with an adjusted p-value < 0.001.
Figure 4. Subtype specific miRNAs can be either oncogenic or representative for the differentiation arrest of 
lymphoblasts. (a + c) Box plots showing the expression of the immature T-ALL specific miRNAs hsa-miR-
126-5p and hsa-miR-222-3p in the immature T-ALL patients and the thymocyte subsets. (b + d) Box plots 
showing the expression of the TAL-R T-ALL specific miRNAs hsa-miR-16-2-3p and hsa-miR-450b-5p in the 
TAL-R T-ALL patients and the thymocyte subsets. *Significant difference with an adjusted p-value < 0.05; 
**significant difference with an adjusted p-value < 0.001.
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Discussion
More than a decade ago, Ferrando et al. and Soulier et al. described different T-ALL subtypes according to specific 
transcriptional profiles1, 2. Last year, we were able to show that these molecular genetic subtypes of human T-ALL 
also display unique long non-coding RNA expression signatures5. Here, we performed small RNA-sequencing on 
48 T-ALL patient samples to finalize the transcriptional characterization of human T-ALL by a comprehensive 
analysis of miRNA expression in this disease.
Small RNA-sequencing enabled the detection of miRNAs that were not included in a previous RT-qPCR anal-
ysis of the same patient population10. Although most of the newly detected miRNAs in T-ALL were expressed at 
very low levels, we also identified a selection of novel T-ALL miRNAs with very high expression levels in T-ALL 
patient samples, including hsa-miR-181b-5p, hsa-miR-423-3p, hsa-miR-486-5p and hsa-miR-92b-3p (Fig. 1b). 
Interestingly, some of these miRNAs have previously been associated with malignant transformation in different 
tumor entities. For example, hsa-miR-181b-5p is a known oncogene in several cancer types as reviewed by Liu 
et al.20. In the context of leukemia, overexpression of hsa-miR-181b-5p was shown to enhance proliferation in 
acute myeloid leukemia by targeting MLK2. Furthermore, hsa-miR-92b-3p was identified as an oncomiR in glio-
blastoma by targeting SMAD321, which is known to be lost in several cases of pediatric T-ALL22, and PTEN23, a 
well-established T-ALL oncosuppressor24, 25. In addition, hsa-miR-92b-3p is also specifically higher expressed in 
TLX1/3 T-ALL compared to the other T-ALL subtypes.
Interestingly, small RNA-sequencing also detects deviations from canonical miRNA sequences. Indeed, 
our analysis revealed 2139 different isomiR forms, corresponding to 481 miRNAs. Remarkably, for only half 
of the miRNAs, the canonical form showed the highest expression (Fig. 1e). In addition, most highly expressed 
isomiRs displayed modifications at their 3′ end, suggesting that these alterations would not affect the miRNA seed 
sequence and, therefore, have no functional effect on target recognition. Nevertheless, a number of studies have 
shown that these 3′ modifications might impact target specificity and stability of the miRNA17, 26.
Finally, small RNA sequencing of human CD34+ and CD4+CD8+ thymocytes enabled the identification of 
subtype specific and oncogenic miRNAs in the context of human T-ALL. An interesting example is hsa-miR-486. 
Hsa-miR-486-5p is one of the highest expressed newly identified miRNAs in T-ALL (Fig. 1b) and, together 
with hsa-miR-486-3p, it also shows higher expression in T-ALL samples as compared to healthy donor thymo-
cytes. Hsa-miR-486-5p is an oncomiR in Down syndrome myeloid leukemias, where it is regulated by GATA127. 
Hsa-miR-486-3p has also been linked to erythroid development downstream of MYB, a known oncogene in 
T-ALL, and targeting MAF28. The differences in miRNA expression could however also be due to the underrep-
resentation of normal thymocyte differentiation stages in this study. Additional experiments are thus needed to 
prove the oncogenic nature of the differentially expressed miRNAs.
Altogether, this study provides the first comprehensive overview of miRNA expression in molecular-genetic 
subtypes of human T-ALL. Integration of these signatures with miRNA expression profiles in normal T-cell sub-
sets provides a unique resource to study novel miRNAs that are implicated in T-ALL disease biology.
Materials and Methods
Study design. Small RNA-sequencing was performed on 48 primary T-ALL patient samples, 7 T-ALL 
cell lines and 2 CD34+ and 2 CD4+CD8+ healthy donor thymocyte subsets, to profile the full T-ALL miRNA 
transcriptome.
Figure 5. Novel oncogenic miRNAs are detected by small RNA-sequencing. (a) Diagonal plot showing the 
expression of the miRNAs in T-ALL compared to healthy donor thymocytes. Red dots represent miRNAs that 
are significantly higher expressed in the T-ALL patient samples, blue dots are the miRNAs significantly higher 
expressed in thymocyte subsets. (b) Top 10 most significantly upregulated miRNAs in the T-ALL patients 
and in the healthy donor samples. MiRNAs denoted in red were not detected by a previously used RT-qPCR 
platform. (c) Dot plots of two representative miRNAs from the table. **Significant difference with an adjusted 
p-value < 0.001.
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Primary human T-ALL patient samples and T-ALL cell lines. Blood samples and bone marrow lymph-
oblast from T-ALL patients were collected after informed consent according to the Declaration of Helsinki from 
Saint-Louis Hospital, Paris, France. This study was approved by both the Institut Universitair d’Hématologie 
Institutional Review Board and the Ethical Committee of Ghent University Hospital. Total RNA was isolated 
using the miRNeasy mini kit (Qiagen). These samples are part of a cohort previously investigated by mRNA29 
and lncRNA profiling5, 30. The T-ALL cell lines LOUCY, DND-41, HPB-ALL, ALL-SIL, PF-382 and JURKAT were 
purchased from DSMZ. KE-37 was a kind gift from the Cools lab.
Thymocyte subset selection. Thymus tissue was derived from children undergoing cardiac surgery (UZ 
Gent) and was obtained and used with informed consent and according to the guidelines of the Medical Ethical 
Commission of Ghent University Hospital (Ghent, Belgium). Both thymocyte subsets were each purified from 
different healthy donors in order to obtain two independent replicates for each subset. Immature CD34+ thy-
mocytes were purified based on MACS purification using CD34 microbeads (Miltenyi Biotec)31 without lineage 
depletion, while CD4 and CD8 labeling was used to sort the CD4+CD8+ double positive subset by a FACSAriaIII 
(BDBiosciences)32. The purity of each subset was at least 98%. Total RNA was isolated using the miRNeasy mini 
kit (Qiagen).
MicroRNA profiling by small RNA-sequencing. The libraries for small RNA-sequencing were prepared 
using the TruSeq small RNA library kit from Illumina with 50 ng of total RNA as input for T-ALL samples and 
100 ng of total RNA as input for T-ALL cell lines and thymocyte subset samples. According to the manufacturer’s 
use, 3′ and 5′ RNA adapters were ligated to the RNA followed by reverse transcription and PCR amplification 
(with bar-coded primers). The PCR products were separated using a Pippin Prep System to recover the 147 nt 
and 157 nt fractions. Sequencing of the small RNA libraries was performed on a NextSeq500 (Illumina), with an 
average of 14.4 million reads per sample. After read quality control and adapter trimming, reads were mapped 
to the reference genome (GRCh38) using Bowtie33. Raw data files are submitted into the GEO database34 with 
accession number GSE89978.
Differential expression analysis. MicroRNA expression data was filtered with a background correction 
that only retained miRNAs detected by at least 4 reads in at least 60% of samples from one T-ALL subgroup or in 
at least all samples from one thymocyte subset. Differential expression analysis was performed using the DESeq2 
algorithm in R35. The expression was normalized using de Variance Stabilizing Transformation from the DESeq2 
algorithm.
Data availability. Reviewers can access the data submitted to the GEO database trough this private link: 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=kzszmioallifrmv&acc=GSE89978.
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